Abstract | BACKGROUND: METHODOLOGY: In this prospective, open-label, pilot study, 20 type-2 diabetes mellitus patients (male/female=13/7, mean age- 56.1±8.04 years), meeting inclusion/exclusion criteria, were treated with dipeptidyl peptidase-4 (DPP-4) inhibitor, Teneligliptin, 20mg once a day for three months. Efficacy parameters: Sudomotor function (Sudoscan score); parasympathetic dysfunction assessed using Ewing's criteria i.e. heart rate response to -standing (HRS), -valsalva (HRV) and -deep breath (HRD); sympathetic dysfunction assessed as blood pressure response to -standing (BPS) and -handgrip (BPH); ankle brachial index (ABI), vibration perception threshold (VPT), C-reactive protein, glycemic profile and health related quality of life (HRQoL); and, tolerability parameters: complete blood count, liver function tests, serum creatinine, thyroid stimulating hormone, QT- interval and serum vitamin B12 levels, were measured. RESULTS: There was no statistical difference in BMI, SBP, DBP, HRD, BPH and all safety parameters. After 12 weeks treatment, there was improvement in HRS (p<0.01) and HRV (p<0.01), but not in HRD (p=0.12). BPS was significantly lowered (p <0.01), but not the BPH (p =0.06). Sudoscan score was increased, while VPT was significantly decreased (both p<0.01). CONCLUSION:
|
Authors | Ashit Syngle, Simran Chahal, Kanchan Vohra |
Journal | Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
(Neurol Sci)
Vol. 42
Issue 4
Pg. 1429-1436
(Apr 2021)
ISSN: 1590-3478 [Electronic] Italy |
PMID | 32803534
(Publication Type: Clinical Trial, Journal Article)
|
Chemical References |
- 3-(4-(4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl)pyrrolidin-2-ylcarbonyl)thiazolidine
- Dipeptidyl-Peptidase IV Inhibitors
- Pyrazoles
- Thiazolidines
- DPP4 protein, human
- Dipeptidyl Peptidase 4
|
Topics |
- Autonomic Nervous System Diseases
- Diabetes Mellitus, Type 2
(complications, drug therapy)
- Diabetic Neuropathies
(drug therapy)
- Dipeptidyl Peptidase 4
- Dipeptidyl-Peptidase IV Inhibitors
(therapeutic use)
- Female
- Hand Strength
- Humans
- Male
- Middle Aged
- Pilot Projects
- Prospective Studies
- Pyrazoles
- Quality of Life
- Thiazolidines
|